Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Vytorin Study Stallin' - Notes from the Field HandsPosted: November 26, 2007At issue here is whether or not adding Zetia to a statin (as in Vytorin, which combines Zetia with Merck's Zocor) reduces plaque in arteries and therefore would help prevent heart attacks and strokes. I thought it would be interesting to see what the Schering-Plough and Merck sales reps are saying about this over at Cafe Pharma. What struck a chord with me was how the alleged stalling tactics are affecting the credibility of sales reps in the field. For more on this, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Increase Physician Access and Detailing Effectiveness
Everyone knows that pharma sales reps are less effective than they used to be. Although the pharmaceutical sales force has doubled between 1995 and 2000, the number of audited calls has only increased by 10%.
Through articles and real-world case studies this Special Supplement to Pharma Marketing News presents the collective wisdom of many marketing experts who offer solutions to the problem of decreasing sales rep effectiveness and decreasing return on the physician marketing dollar.
Order and pay for this Special Supplement now using your credit card. ONLY $29.95 Printable Order Form |